FDA reviews GSK depemokimab for asthma and CRSwNP, with a decision expected by December 2025. Phase 3 data shows improvements.
GSK’s Twice-Yearly Depemokimab Reduces Nasal Polyp Size, Goes Under FDA Review
Where Today's News Shapes Tomorrow
February 13, 2026
Headlines
